JPWO2019131964A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019131964A5 JPWO2019131964A5 JP2019562482A JP2019562482A JPWO2019131964A5 JP WO2019131964 A5 JPWO2019131964 A5 JP WO2019131964A5 JP 2019562482 A JP2019562482 A JP 2019562482A JP 2019562482 A JP2019562482 A JP 2019562482A JP WO2019131964 A5 JPWO2019131964 A5 JP WO2019131964A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- peg
- formula
- residue
- acid residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000539 amino acid group Chemical group 0.000 claims 48
- 102000000588 Interleukin-2 Human genes 0.000 claims 43
- 108010002350 Interleukin-2 Proteins 0.000 claims 43
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 238000000034 method Methods 0.000 claims 23
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 10
- 239000004472 Lysine Substances 0.000 claims 8
- -1 o-azidobenzyl Chemical group 0.000 claims 8
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 8
- 235000004279 alanine Nutrition 0.000 claims 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 2
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017252224 | 2017-12-27 | ||
| JP2017252224 | 2017-12-27 | ||
| PCT/JP2018/048361 WO2019131964A1 (ja) | 2017-12-27 | 2018-12-27 | Ｉｌ－２改変体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2019131964A1 JPWO2019131964A1 (ja) | 2020-12-10 |
| JPWO2019131964A5 true JPWO2019131964A5 (https=) | 2022-10-31 |
| JP7275049B2 JP7275049B2 (ja) | 2023-05-17 |
Family
ID=67067530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019562482A Active JP7275049B2 (ja) | 2017-12-27 | 2018-12-27 | Ｉｌ－２改変体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12280118B2 (https=) |
| EP (1) | EP3733693A4 (https=) |
| JP (1) | JP7275049B2 (https=) |
| KR (1) | KR102740971B1 (https=) |
| CN (1) | CN111868079B (https=) |
| AU (1) | AU2018394189B2 (https=) |
| CA (1) | CA3086842A1 (https=) |
| TW (1) | TW201930345A (https=) |
| WO (1) | WO2019131964A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| KR20240141853A (ko) | 2017-08-03 | 2024-09-27 | 신톡스, 인크. | 자가면역 질환의 치료를 위한 사이토카인 접합체 |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CN111918665B (zh) | 2018-03-28 | 2024-11-26 | 阿森迪斯药物肿瘤股份有限公司 | Il-2缀合物 |
| AU2019301697A1 (en) * | 2018-07-13 | 2021-01-07 | Il-2Rx, Inc. | Compounds, compositions, methods, and uses for treating cancer and immunological disorders |
| CA3098930A1 (en) | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| SG11202102930YA (en) | 2018-11-08 | 2021-04-29 | Synthorx Inc | Interleukin 10 conjugates and uses thereof |
| EP3923974A4 (en) | 2019-02-06 | 2023-02-08 | Synthorx, Inc. | IL-2 CONJUGATES AND METHODS OF USE THEREOF |
| BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| EP4013777A4 (en) * | 2019-08-15 | 2024-01-17 | Cytimm Therapeutics, Inc. | MODIFIED INTERLEUKIN 2 (IL-2) POLYPEPTIDES, CONJUGATES AND USES THEREOF |
| EP4017540A1 (en) | 2019-08-23 | 2022-06-29 | Synthorx, Inc. | Il-15 conjugates and uses thereof |
| US12234271B2 (en) | 2019-09-10 | 2025-02-25 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
| CN114437198A (zh) * | 2019-12-17 | 2022-05-06 | 北京志道生物科技有限公司 | 白介素-2衍生物 |
| WO2021143572A1 (zh) * | 2020-01-15 | 2021-07-22 | 天津键凯科技有限公司 | 一种制备结合位点可控的peg化生物分子的方法 |
| EP4107187A4 (en) | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR |
| PE20231648A1 (es) * | 2020-04-22 | 2023-10-17 | Merck Sharp And Dohme Llc | CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DIMERO DEL RECEPTOR DE INTERLEUCINA 2 byc Y CONJUGADOS CON UN POLIMERO HIDROSOLUBLE NO PEPTIDICO |
| KR20230019889A (ko) | 2020-06-03 | 2023-02-09 | 아센디스 파마 온콜로지 디비전 에이/에스 | Il-2 서열 및 이의 용도 |
| CA3195612A1 (en) * | 2020-10-14 | 2022-04-21 | Haining HUANG | Modified interleukin 2 (il-2) polypeptides, and methods of making and using the same |
| CN113698468B (zh) * | 2021-09-01 | 2022-10-11 | 浙江新码生物医药有限公司 | 人白细胞介素2-聚乙二醇偶联物及其应用 |
| EP4406965A4 (en) * | 2021-09-22 | 2025-12-17 | Fortvita Biologics Singapore Pte Ltd | INTERLEUKIN-2 MUTANT AND FUSION PROTEIN OF WHICH |
| CN116769013A (zh) * | 2022-03-10 | 2023-09-19 | 广东菲鹏制药股份有限公司 | 白细胞介素2突变体以及含有其的复合物 |
| CN115850436B (zh) * | 2022-10-14 | 2026-02-03 | 海徕科(北京)生物技术有限公司 | 白介素2突变体及其应用 |
| CN120603842A (zh) * | 2022-11-30 | 2025-09-05 | 砭石生物制药有限公司 | Il-2突变体及其用途 |
| JPWO2025009591A1 (https=) * | 2023-07-06 | 2025-01-09 | ||
| WO2025148785A1 (en) * | 2024-01-08 | 2025-07-17 | Fbd Biologics Limited | Engineered il-2 variants and methods of use thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1388836A (en) | 1971-06-01 | 1975-03-26 | Medisan Ab | Cosmetic compositions |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| JP2524586B2 (ja) | 1985-06-26 | 1996-08-14 | シタス コーポレイション | ポリマ−接合を利用する医薬組成物用蛋白質の可溶化 |
| US5417970A (en) | 1988-10-21 | 1995-05-23 | Sanofi | Drugs containing a glycosylated interleukin-2 |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5153310A (en) | 1989-02-28 | 1992-10-06 | Du Pont Merck Pharmaceutical Company | Il-2 analogs containing n-linked glycosylation sites |
| US5312903A (en) | 1990-06-01 | 1994-05-17 | E. I. Du Pont De Nemours And Company | Lysine-glycosylated recombinant interleukin-2 |
| ES2297889T3 (es) * | 1997-07-14 | 2008-05-01 | Bolder Biotechnology, Inc. | Derivados de hormona de crecimiento y proteinas relacionadas. |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| US7070959B1 (en) * | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| CA2451971C (en) | 2001-06-19 | 2010-09-07 | Otsuka Chemical Co., Ltd. | Process for producing sugar chain asparagine derivative |
| WO2003012036A2 (en) | 2001-07-27 | 2003-02-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Systems for in vivo site-directed mutagenesis using oligonucleotides |
| DK1454138T3 (da) | 2001-12-04 | 2012-02-13 | Merck Patent Gmbh | Immunocytokiner med moduleret selektivitet |
| US7943763B2 (en) | 2002-07-05 | 2011-05-17 | Otsuka Chemical Holdings Co., Ltd. | Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides |
| DE602004017726D1 (de) * | 2003-06-30 | 2008-12-24 | Domantis Ltd | Pegylierte Single-domain-antikörper (dAb) |
| US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| CA2533849C (en) | 2003-07-28 | 2013-07-02 | Otsuka Chemical Co., Ltd. | Aminated complex-type sugar chain derivatives and process for the production thereof |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| AU2010206840B2 (en) | 2009-01-21 | 2015-02-05 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| WO2012065086A1 (en) | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| EP2859017B1 (en) * | 2012-06-08 | 2019-02-20 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| WO2014028748A1 (en) | 2012-08-15 | 2014-02-20 | Irm Llc | Interleukin 2 antibodies and antibody complexes |
| EP2898085B1 (en) | 2012-09-24 | 2019-01-23 | MedImmune Limited | Cell lines |
| WO2014124258A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
| US9580486B2 (en) * | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
| PT3172227T (pt) | 2014-07-21 | 2019-12-06 | Delinia Inc | Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis |
| AU2015301936B2 (en) | 2014-08-11 | 2019-03-07 | Delinia, Inc. | Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases |
| EP3360960A4 (en) | 2015-08-19 | 2019-03-20 | Riken | ANTIBODIES WITH INGREDIENTS OF NON-NATURAL AMINO ACID |
| JP7422480B2 (ja) * | 2016-05-04 | 2024-01-26 | アムジエン・インコーポレーテツド | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
-
2018
- 2018-12-27 US US16/958,045 patent/US12280118B2/en active Active
- 2018-12-27 EP EP18897857.1A patent/EP3733693A4/en active Pending
- 2018-12-27 CA CA3086842A patent/CA3086842A1/en active Pending
- 2018-12-27 JP JP2019562482A patent/JP7275049B2/ja active Active
- 2018-12-27 TW TW107147546A patent/TW201930345A/zh unknown
- 2018-12-27 WO PCT/JP2018/048361 patent/WO2019131964A1/ja not_active Ceased
- 2018-12-27 KR KR1020207018206A patent/KR102740971B1/ko active Active
- 2018-12-27 AU AU2018394189A patent/AU2018394189B2/en active Active
- 2018-12-27 CN CN201880083560.4A patent/CN111868079B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019131964A5 (https=) | ||
| JP7275049B2 (ja) | Ｉｌ－２改変体 | |
| ES2374166T3 (es) | Dominios sushi de il-15ralfa como potenciadores selectivos y eficaces de la acción de il-15 a través de il-15rbeta/gamma, en las prote�?nas de fusión hiperagonistas il15ralfa sushi-il 15. | |
| JP2017523789A5 (https=) | ||
| CN105324397B (zh) | 胰岛素-肠促胰岛素缀合物 | |
| RU2015101697A (ru) | Аналоги глюкагона, обладающие активностью рецептора gip | |
| RU2012101274A (ru) | Соединения глюкагона, активные в отношении рецептора gip | |
| RU2011147083A (ru) | Новый вариант эксендина и его конъюгат | |
| RU2017101436A (ru) | Mic-1 слитные белки и их применение | |
| CN108271356A (zh) | 肠降血糖素-胰岛素缀合物 | |
| JP2016512213A5 (https=) | ||
| KR20170068553A (ko) | 인터류킨-15 조성물 및 이의 용도 | |
| RU2014101697A (ru) | Коагонисты рецепторов глюкагона/glp-1 | |
| JP2006515579A5 (https=) | ||
| JP2014525901A5 (https=) | ||
| JP2005530732A5 (https=) | ||
| JP2015520128A5 (https=) | ||
| RU2014127270A (ru) | Аналог человеческого инсулина и его ацилированное производное | |
| Romano et al. | Molecular cloning and characterization of CD4 in an aquatic mammal, the white whale Delphinapterus leucas | |
| RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| EP2185584A1 (en) | Interferon fusion proteins | |
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE | |
| JP2020518249A5 (https=) | ||
| EP1673387B1 (en) | Il-21 derivatives | |
| JP2012518669A5 (https=) |